CStone Pharmaceuticals (HKG: 2616), a China – based biopharmaceutical company focused on oncology drug development, announced on January 27 a strategic commercialization partnership with SteinCares, a leading pharmaceutical company in the Latin American market. Under the licensing and commercialization agreement, SteinCares will obtain the rights to commercialize sugemalimab in 10 Latin American countries, including Brazil, Argentina, Mexico, Chile, Colombia, Costa Rica, Panama, Peru, Guatemala, and Ecuador.
Partnership Details
In the collaboration, SteinCares will be responsible for the registration and commercialization activities of sugemalimab in the specified Latin American region. CStone Pharmaceuticals will supply the product and receive upfront payments, registration and sales milestone payments from SteinCares, as well as generate international revenue through sales of sugemalimab to SteinCares.-Fineline Info & Tech
